Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies
暂无分享,去创建一个
S. Ansell | L. Miller | H. Lichenstein | J. Abramson | D. Aboulafia | C. Diefenbach | T. Sher | S. Rutherford | D. Nix | N. Lakhani | M. Schreeder | S. Landrette | W. Harb | J. Cohen | Kate Flanders